Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
The Cochrane Database of Systematic Reviews|May 3, 2024
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsRobin Wm Vernooij, Mini Michael, Maleeka Ladhani, et al.The Cochrane Database of Systematic Reviews|January 14, 2025
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsRobin Wm Vernooij, Mini Michael, Julia Mt Colombijn, et al.Clinical Kidney Journal|September 9, 2020
Erratum: Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13Mini Michael, Nancy Turner, Ewa Elenberg, et al.Clinical Kidney Journal|December 8, 2018
Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13Mini Michael, Nancy Turner, Ewa Elenberg, et al.Urolithiasis|May 14, 2020
Are conventional stone analysis techniques reliable for the identification of 2,8-dihydroxyadenine kidney stones? A case seriesHrafnhildur L Runolfsdottir, Tzu-Ling Lin, David S Goldfarb, et al.Frontiers in Pediatrics|October 2, 2024
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trialYaacov Frishberg, Wesley Hayes, Hadas Shasha-Lavsky, et al.Pediatric Nephrology (Berlin, Germany)|May 16, 2024
Diagnosis and management of primary hyperoxalurias: best practicesMini Michael, Elizabeth Harvey, Dawn S Milliner, et al.Pediatric Nephrology (Berlin, Germany)|August 1, 2022
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trialWesley Hayes, David J Sas, Daniella Magen, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young childrenDavid J Sas, Daniella Magen, Wesley Hayes, et al.Pediatric Nephrology (Berlin, Germany)|January 23, 2023
Genetic testing in children with nephrolithiasis and nephrocalcinosisAshley M Gefen, Christine B Sethna, Onur Cil, et al.Pageof 3